Intensity Therapeutics, Inc.
INTSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeIntensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United. The company carries a $10.6M market cap, placing it firmly in the micro-cap category. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.
Market Cap
$10.6M
Beta
3.08
P/E (TTM)
—
P/E (Fwd)
-1.63
EPS (TTM)
$-3.89
EPS (Fwd)
$-1.99
ROE
-195.9%
ROA
-89.9%
Cash
$9.5M
Total Debt
$95,000
Free CF
-$6.3M
52W Change
-45.4%
Annual Financials
Cash vs Debt
Where INTS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, INTS finished 27.21% below its 150-day moving average ($4.52) and 40.61% below its 200-day moving average ($5.54). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INTS overbought or oversold?
At the October 20, 2026 close, INTS's RSI(14) was 46.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Intensity Therapeutics, Inc. holds $9.5M in cash against $95K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$6.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -195.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta above 1.5, INTS tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing INTS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.